SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial
Primary result · FBF response to SNP (endothelium-independent vasodilation)Result — go to the resultGeometric mean ratio 1.21 95% CI 1.09–1.33Authors' conclusion
Empagliflozin improves endothelium-independent vasodilation, reduces vascular resistance and lowers 24-h BP in patients with T2DM, whereas no change in endothelial-dependent vasodilation was observed.
Study context
- Population
- Patients with T2D; mean age 68 ± 8 years, 69% male16 completed
- Comparison
- Empagliflozin 10 mg vs placebo, 4 weeks each, 2-week washout
Methodological detailsdouble-blind, placebo-controlled, crossover
- Double-blind
- Placebo-controlled
- Crossover
Primary result
As reported in the abstract
Forearm blood flow (FBF) response to SNP (endothelium-independent vasodilation) · after each 4-week treatment period
Geometric mean ratio
1.21
95% CI 1.09–1.33
P ≤ 0.001
Empagliflozinvs Placebo
geometric mean ratio 1.21 (95% CI 1.09–1.33); P ≤ 0.001
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| FBF response to acetylcholine (endothelium-dependent vasodilation)No increase | P = 0.290 | |
| 24-h systolic BPLower with Empagliflozin | decrease 5 mmHg (95% CI −9 to −1) | P = 0.015 |
| 24-h diastolic BPLower with Empagliflozin | decrease 2 mmHg (95% CI −5 to 0) | P = 0.029 |
| Systemic vascular resistanceLower with Empagliflozin | decrease 48 dyn×s/m5 (95% CI −94 to −1) | P = 0.044 |
Nitric oxide (NO) activity markers
- Empagliflozin reduced plasma nitrite and urinary NOx
Original publication
SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial. Diabetes Obes Metab. Published 29 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →